Aardvark Therapeutics, Inc. Common Stock (AARD) Research

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Market snapshot

Symbol
AARD
Price
$3.93
Day change
+2.88%
Market cap
$85.7M
P/E ratio
-1.23x
52-week range
3.35-17.94
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$22.75

Recent news

  • FDA Halts Aardvark Therapeutics Rare Disease Study

    Aardvark Therapeutics Inc. (NASDAQ:AARD) said the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application for ARD-101, following the company's previously disclosed voluntary program pause.

  • FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

    Aardvark Therapeutics on Thursday said the U.S. Food and Drug Administration placed a full ​clinical hold on its drug to treat ‌extreme hunger linked to the rare disorder Prader-Willi syndrome, halting all late-stage trials.

Peer companies

  • Assembly Biosciences, Inc. (ASMB)
  • Avalo Therapeutics, Inc. (AVTX)
  • Caribou Biosciences, Inc. (CRBU)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Eupraxia Pharmaceuticals Inc. (EPRX)
  • Foghorn Therapeutics Inc. (FHTX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Pyxis Oncology, Inc. (PYXS)

Recent insider activity

  • Sun Nelson — A-Award (70549 shares) on 2026-02-09
  • Jaiman Manasi — A-Award (70549 shares) on 2026-02-09
  • Lee Tien-Li — A-Award (203851 shares) on 2026-02-09
  • Sun Nelson — P-Purchase (3000 shares) on 2025-12-11
  • Lee Tien-Li — P-Purchase (7000 shares) on 2025-12-11

Open Aardvark Therapeutics, Inc. Common Stock (AARD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.